The clinical failure-strewn world of Alzheimer's disease (AD) awaits top-line, part A results due in April from Vtv Therapeutics Inc.'s phase III study called Steadfast with azeliragon, an antagonist of the receptor for advanced glycation end products (RAGE), and many hope the new approach can break through the development wall that other drug candidates have splattered themselves against.